KCNA3 and ischemic stroke: In our efforts to translate KV1.3 into a therapeutic target for ischemic stroke, we initially performed proof-of-concept experiments in young male mice, where we characterized the time course of KV1.3 expression on microglia after MCAO and demonstrated that PAP-1 treatment started at 12 h after reperfusion decreased infarct size and improved neurological deficits after 1 week (Chen et al., 2018).